T. Rowe Price Associates’s Immunome IMNM Stock Holding History

T. Rowe Price Associates’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62.5M	Sell	2,858,863 -521,377	-15%	-$11.6M	0.01%	717
2025 Q4	$72.6M	Sell	3,380,240 -362,530	-10%	-$6.36M	0.01%	703
2025 Q3	$43.8M	Buy	3,742,770 +760,690	+26%	+$7.57M	﹤0.01%	844
2025 Q2	$27.7M	Sell	2,982,080 -87,527	-3%	-$718K	﹤0.01%	886
2025 Q1	$20.7M	Buy	3,069,607 +786,853	+34%	+$7.55M	﹤0.01%	945
2024 Q4	$24.2M	Buy	2,282,754 +246,447	+12%	+$2.98M	﹤0.01%	948
2024 Q3	$29.8M	Buy	2,036,307 +15,188	+0.8%	+$216K	﹤0.01%	896
2024 Q2	$24.5M	Sell	2,021,119 -224,554	-10%	-$3.51M	﹤0.01%	905
2024 Q1	$55.4M	Buy	2,245,673 +1,194,451	+114%	+$24.2M	0.01%	706
2023 Q4	$11.2M	Buy	1,051,222 +877,592	+505%	+$7.3M	﹤0.01%	1073
2023 Q3	$1.45M	Buy	+173,630	New	+$1.28M	﹤0.01%	1619
2021 Q4	–	Sell	-10,800	Closed	-$263K	–	3012
2021 Q3	$263K	Buy	+10,800	New	+$188K	﹤0.01%	2623

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

T. Rowe Price Associates's IMNM Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Immunome (IMNM) stake by 15% in Q1 2026, selling an estimated $11.6M and leaving 2,858,863 shares worth $62.5M. The position accounts for 0.01% of the portfolio, ranked #717.

T. Rowe Price Associates first reported a position in IMNM in Q3 2021 and has held it in 12 quarters since. The position peaked at $72.6M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

T. Rowe Price Associates held 2,858,863 shares of Immunome worth $62.5M as of Q1 2026.
T. Rowe Price Associates sold 521,377 Immunome shares in Q1 2026, an estimated $11.6M.
Immunome made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #717 holding.
T. Rowe Price Associates first reported a position in Immunome in Q3 2021 and has held it in 12 quarters since.
T. Rowe Price Associates's Immunome position peaked at $72.6M in Q4 2025.
200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.